Market Reports /
by Peter Milios -
A year ago
30 Jan 2023 - The global race for lithium, a commodity crucial for the electric vehicle (EV) industry, has intensified as German Chancellor Olaf Scholz signed an agreement with Arg…
Company Presentations /
by Finance News Network -
A year ago
24 Oct 2022 - Dr. Steven Gourlay - Managing Director & CEO - Actinogen Medical is a biotechnology company developing an innovative treatment for cognitive impairment associated wit…
Market Reports /
by Peter Milios -
A year ago
10 Oct 2022 - It was a poor start to the week, as all sectors finished in the red, falling by 1.4 per cent or 95 basis points to 6667.80.
Market Reports /
by Lauren Hayes -
A year ago
10 Oct 2022 - It was always going to be a dismal start to the trading week following Wall Street tumbling on Friday, after a stronger-than-expected jobs report raised the likelihoo…
Interviews /
by Rachael Jones -
3 years ago
11 Nov 2020 - Actinogen Medical Limited (ASX:ACW) Managing Director and CEO Dr Bill Ketelbey provides an update on the company, discussing its lead drug candidate Xanamem, clinical…
Company Presentations /
by -
4 years ago
31 Jul 2020 - Actinogen Medical Limited (ASX:ACW) CEO and Managing Director, Dr Bill Ketelbey talks about Xanamem, XanaHES trial and potential partnerships.
Interviews /
by Rachael Jones -
5 years ago
25 Sep 2018 - Actinogen Medical Limited (ASX:ACW) Managing Director and CEO, Dr Bill Ketelbey provides an update on the company's lead Alzheimer Phase II drug candidate XanADu and …
Company Presentations /
by -
5 years ago
24 Sep 2018 - Actinogen Medical Limited (ASX:ACW) Managing Director and CEO, Dr Bill Ketelbey presents an update on the company's lead Alzheimer Phase II drug candidate XanADu and …
Market Reports /
by David Chau -
7 years ago
03 Jan 2017 - Strong finish: ASX up 1.19% on first trading day. Hills Ltd (ASX:HIL) enters contract with AMES Australasia, who will now manufacture and sell the Hills Home Living p…
Company News /
by David Chau -
7 years ago
03 Jan 2017 - US Food and Drug Administration (FDA) approves Actinogen Medical’s (ASX:ACW) application to start a Phase II clinical trial of its Alzheimer's drug, Xanamem.
Market Reports /
by David Chau -
7 years ago
30 Dec 2016 - Gold miners rally: ASX is 0.35% lower before noon. Shine Corporate Ltd (ASX:SHJ) announces its founders will return to key roles after the resignation of Managing Dir…
Interviews /
by -
9 years ago
23 Jun 2015 - Actinogen Limited (ASX:ACW) CEO Dr Bill Ketelbey provides an update on the company’s development of treatment for Alzheimer’s disease.
Interviews /
by Lelde Smitts -
9 years ago
27 April 2015 - Actinogen Limited (ASX:ACW) CEO Dr Bill Ketelbey discusses how the company is pursuing treatment of Alzheimer’s disease.
Company News /
by -
9 years ago
24 Apr 2015 - Actinogen Limited (ASX:ACW) raises $10 million through an institutional placement that will go towards a Phase II trial of its promising Alzheimer drug Xanamem.
Market Reports /
by -
9 years ago
24 Mar 2015 - ASX higher despite US losses. Biotechnology company Actinogen Limited (ASX:ACW) announces positive results from a clinical trial of the Xanamem alzheimers dementia dr…